Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Pharmacology and Experimental Therapeutics
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Journal of Pharmacology and Experimental Therapeutics

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit jpet on Facebook
  • Follow jpet on Twitter
  • Follow jpet on LinkedIn
Research ArticleCARDIOVASCULAR

Pharmacological Profile of the Novel Inotropic Agent (E,Z)-3-((2-Aminoethoxy)imino)androstane-6,17-dione Hydrochloride (PST2744)

R. Micheletti, G. G. Mattera, M. Rocchetti, A. Schiavone, M. F. Loi, A. Zaza, R. J. P. Gagnol, S. De Munari, P. Melloni, P. Carminati, G. Bianchi and P. Ferrari
Journal of Pharmacology and Experimental Therapeutics November 2002, 303 (2) 592-600; DOI: https://doi.org/10.1124/jpet.102.038331
R. Micheletti
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
G. G. Mattera
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
M. Rocchetti
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
A. Schiavone
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
M. F. Loi
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
A. Zaza
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
R. J. P. Gagnol
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
S. De Munari
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
P. Melloni
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
P. Carminati
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
G. Bianchi
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
P. Ferrari
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

The novel Na+/K+-ATPase inhibitor (E,Z)-3-((2-aminoethoxy)imino)androstane-6,17-dione hydrochloride (PST2744) was characterized for its inotropic and toxic properties. Inhibition potency on dog kidney Na+/K+-ATPase was comparable (0.43 μM) to that of digoxin (0.45 μM). PST2744 concentration-dependently increased force of contraction in guinea pig atria and twitch amplitude in isolated guinea pig myocytes; in the latter, aftercontractions developed significantly less than with digoxin. Intravenous infusion of 0.2 mg/kg/min PST2744 in anesthetized guinea pigs exerted an immediate and long-lasting inotropic effect (ED80 of 1.89 ± 0.37 mg/kg) without causing lethal arrhythmias up to a cumulative dose of 18 mg/kg. Conversely, an equieffective infusion of digoxin (0.016 mg/kg/min; ED80 of 0.32 mg/kg) caused lethal arrhythmias at a cumulative dose of 0.81 mg/kg. At a higher rate (0.4 mg/kg/min), PST2744 induced lethal arrhythmias, with a lethal dose/ED80 ratio significantly greater than digoxin (20.2 ± 6.3 versus 3.23 ± 0.55, p < 0.05). Decay of the inotropic effect (t1/2, min) was significantly faster for PST2744 (6.0 ± 0.39) than for digoxin (18.3 ± 4.5, p < 0.05). In anesthetized dogs, PST2744 dose-dependently increased maximum velocity of pressure rise (+dP/dtmax) in the range 32 to 500 μg/kg i.v. and was safer than digoxin. In conscious dogs with a healed myocardial infarction, PST2744 significantly increased resting values of +dP/dtmax, left ventricular pressure, and SPB, and increased +dP/dtmax throughout treadmill exercise while reverting the increase in left ventricular end diastolic pressure seen in control animals. Digoxin significantly decreased basal heart rate, while not affecting the hemodynamic response to exercise. Thus, PST2744 represents a new class of Na+/K+-ATPase inhibitors endowed with inotropic activity comparable with that of digitalis but having greater safety.

Footnotes

  • DOI: 10.1124/jpet.102.038331

  • Abbreviations:
    HF
    heart failure
    LVP
    left ventricular pressure
    +dP/dtmax
    maximum velocity of pressure rise
    HR
    heart rate
    −dP/dtmax
    maximum velocity of pressure fall
    ED80
    dose increasing +dP/dtmax by 80%
    EDmax
    dose inducing the maximum increase in +dP/dtmax
    LD
    lethal dose
    DMSO
    dimethyl sulfoxide
    bpm
    beats per minute
    LVEDP
    left ventricular end diastolic pressure
    SBP
    systolic blood pressure
    • Received May 9, 2002.
    • Accepted July 3, 2002.
  • The American Society for Pharmacology and Experimental Therapeutics
View Full Text

JPET articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Journal of Pharmacology and Experimental Therapeutics: 303 (2)
Journal of Pharmacology and Experimental Therapeutics
Vol. 303, Issue 2
1 Nov 2002
  • Table of Contents
  • Index by author
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Journal of Pharmacology and Experimental Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Pharmacological Profile of the Novel Inotropic Agent (E,Z)-3-((2-Aminoethoxy)imino)androstane-6,17-dione Hydrochloride (PST2744)
(Your Name) has forwarded a page to you from Journal of Pharmacology and Experimental Therapeutics
(Your Name) thought you would be interested in this article in Journal of Pharmacology and Experimental Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleCARDIOVASCULAR

Pharmacological Profile of the Novel Inotropic Agent (E,Z)-3-((2-Aminoethoxy)imino)androstane-6,17-dione Hydrochloride (PST2744)

R. Micheletti, G. G. Mattera, M. Rocchetti, A. Schiavone, M. F. Loi, A. Zaza, R. J. P. Gagnol, S. De Munari, P. Melloni, P. Carminati, G. Bianchi and P. Ferrari
Journal of Pharmacology and Experimental Therapeutics November 1, 2002, 303 (2) 592-600; DOI: https://doi.org/10.1124/jpet.102.038331

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleCARDIOVASCULAR

Pharmacological Profile of the Novel Inotropic Agent (E,Z)-3-((2-Aminoethoxy)imino)androstane-6,17-dione Hydrochloride (PST2744)

R. Micheletti, G. G. Mattera, M. Rocchetti, A. Schiavone, M. F. Loi, A. Zaza, R. J. P. Gagnol, S. De Munari, P. Melloni, P. Carminati, G. Bianchi and P. Ferrari
Journal of Pharmacology and Experimental Therapeutics November 1, 2002, 303 (2) 592-600; DOI: https://doi.org/10.1124/jpet.102.038331
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Optimized S-nitrosohemoglobin synthesis in red blood cells
  • High-Salt Diet Upregulates CaSR Expression and Signaling
  • L-Arginine improves post-infarction physical function
Show more Cardiovascular

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About JPET
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0103 (Online)

Copyright © 2022 by the American Society for Pharmacology and Experimental Therapeutics